Quantitative MAIPA: Comparison of different MAIPA protocols.
BACKGROUND
In a screening setting, maternal anti-HPA 1a antibody level has been found to be a good prognostic tool to identify newborns at risk for severe NAIT.


OBJECTIVE
Identify the optimal MAIPA protocol for quantitation of anti-HPA 1a antibodies.


METHODS
Plasma were analysed for anti-HPA 1a antibodies using different monoclonal antibodies, lyophilized or fresh platelets and MAIPA protocols.


RESULTS
The anti-HPA 1a antibody level varied significantly when different monoclonal antibodies were used. However, there was a strong correlation between maternal anti-HPA 1a antibody level and platelet count in the newborn. The sensitivity of the assay depended on the adopted MAIPA protocol.


CONCLUSIONS
Consistent tests results are of importance for the clinical impact of the test.
Killie
Mette Kjær
MK
Department of Immunology and Transfusion Medicine, University Hospital of North Norway, 9038 Tromsø, Norway. mette.kjaer.killie@unn.no
Salma
Wahida
W
Bertelsen
Eirin
E
Skogen
Bjørn
B
Husebekk
Anne
A
D000328:Adult; D000911:Antibodies, Monoclonal / Q000737:chemistry; D016824:Antigens, Human Platelet / Q000737:chemistry* / Q000276:immunology; D001792:Blood Platelets / Q000737:chemistry / Q000276:immunology; D005188:False Negative Reactions; D005260:Female; D006720:Homozygote; D006801:Humans; D007118:Immunoassay / Q000379:methods*; D007231:Infant, Newborn; D039661:Integrin beta3; D040201:Platelet Membrane Glycoprotein IIb / Q000737:chemistry; D011379:Prognosis; D011446:Prospective Studies; D054098:Thrombocytopenia, Neonatal Alloimmune / Q000628:therapy*
D000911:Antibodies, Monoclonal; D016824:Antigens, Human Platelet; C061248:ITGB3 protein, human; D039661:Integrin beta3; D040201:Platelet Membrane Glycoprotein IIb